Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Patient-reported outcomes item selection for bladder cancer patients in chemo- or immunotherapy

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Early indicators of primary brain tumours: a population-based study with 10 years’ follow-up

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Optimal Systemic Treatment of Advanced Bladder Cancer-A Moving Target

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Gynaecological cancer leads to long-term sick leave and permanently reduced working ability years after diagnosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The Use of Wearables in Clinical Trials During Cancer Treatment: Systematic Review

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

BACKGROUND: Selection of specific patient-reported outcomes (PROs) for cancer patients requires careful consideration to the purpose and population at aim. Here we report the process of choosing which items to include in a bladder cancer population in chemo- or immunotherapy based on the Patient-Reported Outcomes Version of the Common Terminology Criteria of Adverse Events (PRO-CTCAE).

METHODS: Initial PRO-CTCAE symptoms were chosen through 1) medical record audit 2) patient interviews 3) summary of product characteristics from European Medicines Agency and Food and Drug Administration for the applied chemotherapies, and 4) toxicity reporting from Phase 2 and 3 trials for immunotherapies applied in patients with urothelial cancer. The selected questions were applied in a prospective cohort of 78 bladder cancer patients receiving chemo- or immunotherapy at Rigshospitalet and Herlev Hospital, Denmark. Symptoms tested in this population were selected for the final module if they appeared in ≥3 of the following groupings a) the most prevalent PRO-CTCAE symptoms grade ≥ 2 overall during treatment b) the PRO-CTCAE symptoms reported in conjunction with hospital admissions or mentioned in focus group interviews discussing which symptoms were prevalent in this patient group with specialized c) nurses or d) physicians. The authors also included symptoms in the final module if they were present in two of the above groups and defined as actionable by clinicians.

RESULTS: From the initial selection of PRO-CTCAE symptoms, a total of 45 PRO-CTCAE symptoms explored by 84 PRO-CTCAE questions were retrieved. Through the second selection process based on the described criteria, the study group agreed on 15 PRO-CTCAE symptoms explored by 30 PRO-CTCAE items to be appropriate and relevant for the bladder population during medical oncological treatment.

CONCLUSIONS: The selection of disease specific PROs in a bladder cancer population was feasible. The process revealed several steps of selection needed in order to reach a final module for clinical application.

Original languageEnglish
JournalJournal of Patient-Reported Outcomes
Volume3
Issue number1
Pages (from-to)56
ISSN2509-8020
DOIs
Publication statusPublished - 22 Aug 2019

ID: 59004412